Danaher Corporation: Mixed — EPS $2.11, Revenue $6.55B
Mixed ResultQ3 2026 · Pre-market
@trystockwhiz
Did Danaher Corporation (DHR) beat earnings today?
It was a mixed report for Q3 2026 — Danaher Corporation (DHR) beat on EPS but missed on revenue.
Earnings Per Share+9.90% surprise
$2.11Actual
Expected: $1.92
vs. year ago +11.5%
Total Revenue-0.09% surprise
$6.55BActual
Expected: $6.56B
vs. year ago +8.5%
Released Oct 21 · 6:00 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $6.55B | $6.05B | +8.5% |
| Net earnings | $1.21B | $908.00M | +32.9% |
| Basic EPS | $1.71 | $1.28 | +33.6% |
| Diluted EPS | $1.71 | $1.27 | +34.5% |
| Adjusted Diluted EPS | $2.11 | $1.89 | +11.5% |
Financial Outlook / Guidance
| Metric | Q4 2026 Outlook | FY 2026 Outlook |
|---|---|---|
| Core sales growth | ~+3.0% | ~+2.5% |
| Biotechnology | +Mid-single digit | +Mid-single digit |
| Life Sciences | +4.0% - +5.0% | +3.0% - +4.0% |
| Diagnostics | +Up slightly | ~Flat |
| Respiratory testing | ~+150 basis points | +Low-single digit |
| Core sales growth excluding respiratory testing | +4.0% - +5.0% | +Mid-single digit |
| Adjusted operating profit margin | — | ~29.5% |
| Adjusted diluted net earnings per common share | — | $8.57 - $8.62 (prev. $8.45 - $8.60) |
| Currency exchange rates on sales | ~Flat | ~+1.0% |
| Amortization of acquisition-related intangible assets | ~$(500)M | ~$(1,900)M |
| Corporate expense | ~$(90)M | ~$(355)M |
| Interest expense, net | ~$(120)M | ~$(305)M |
| Average adjusted diluted shares | ~707M | ~708M |
| Respiratory testing sales | ~$400M | ~$1,500M |
Business Highlights
- ➤Julie Sawyer Montgomery transitioned into the Chief Executive Officer role.
- ➤The company emphasized DBS-driven execution across its operations.
- ➤Danaher operates a connected ecosystem of life sciences, diagnostics and biotechnology businesses.
- ➤The company works with customers to accelerate discovery, development and delivery of therapies.
- ➤Danaher reported approximately 60,000 associates worldwide.
- ➤The company cited the Masimo Corporation acquisition in its disclosures.
- ➤Danaher is pursuing leadership in Life Sciences and Diagnostics.
- ➤The company highlighted its focus on improving patient outcomes globally.
Management Commentary
Julie Sawyer Montgomery, President and Chief Executive Officer
“We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance.”
Julie Sawyer Montgomery, President and Chief Executive Officer
“Danaher has built a strong foundation, and the time I've spent with our teams and customers during my transition into the CEO role has only reinforced my conviction in the opportunities ahead. Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world.”